Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 480 participants.

Also called NCT01189890

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 480 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01189890
Main results
  • Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial Drugs & aging, 2015-06 DOI, PubMed 26041585

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01189890. Randomized; double masking; primary purpose treatment. Start 2010-08-16 (actual); primary completion 2012-10-31 (actual). Results posted on 2013-06-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
sitagliptin phosphate
Intervention (Drug)
Glimepiride
Intervention (Drug)
Placebo to Sitagliptin
Intervention (Drug)
Placebo to Glimepiride
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)

Record details

Record id
cardio:ct-nct01189890
Content hash
4c9b60e6282e7c188b5f82b4f449214d80ec19def9f940e8d7ef807e5eb0ae61